NEW YORK, Aug. 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Emerging Pharmaceutical Markets in the Middle East
http://www.reportlinker.com/p0944902/Emerging-Pharmaceutical-Markets-in-the-Middle-East.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical
The report presents and analyzes exclusive survey data from 126 industry executives on industry incentives, commercial environment, and partnership plans. Each country's macroeconomic, pricing and reimbursement, and healthcare environment is described and compared. An attractiveness index allowing comparison of the five countries along four dimensions is also presented.
Forecast pharmaceutical sales for five key
Middle East countries to 2017.
Gain insights into the relative merits of Middle Eastern pharma markets from a survey of 126 executives.
Learn about regional variations in IP protection, infrastructure, and disease burden.
Evaluate pricing and reimbursement environments across the region.
Assess each of the five countries using the Scrip Insights attractiveness index.
Looking at sales forecasts for 2012, Egyptian sales are estimated at
$3.9bn, followed by
Iran (
$2.9bn),
Saudi Arabia (
$2.3bn),
Israel (
$1.5bn), and the UAE (
$1.3bn). On a per capita basis,
Israel and UAE lead the way, due to their comparatively small populations.
The Scrip Insights' survey of pharmaceutical industry insiders found that UAE ranked highly in encouraging foreign investment, while
Iran lagged. For encouraging innovation, 88% of respondents thought that
Israel had put in place enough initiatives to encourage innovation in the domestic biopharma industry.
Compared with 2012, by 2017 the market for pharmaceuticals in UAE is forecast to have risen the most in percentage terms among the five countries, by 115%. The UAE topped the Scrip Insights attractiveness index due to its high growth prospects and government incentives for overseas investment.
How do
Egypt,
Iran,
Saudi Arabia,
Israel, and the UAE compare in terms of healthcare infrastructure, and government incentives for pharma companies?
Which countries have the greatest disease burden?
How do drug prices and per capita pharmaceutical spending vary across the region?
Which countries have the greatest incentives for innovation?
How are political events shaping the market environments across the region?
To order this report:
Pharmaceutical Industry: Emerging Pharmaceutical Markets in the Middle East
More Market Research Report
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article